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Abstract 
Background: Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer‑related death, and new 
prognostic biomarkers are urgently needed. Apoptosis‑stimulating P53‑binding protein 1 (ASPP1) and 2 (ASPP2) have 
been reported to play important roles in the development, progression, metastasis, and prognosis of cancers, but 
their roles in ESCC have not been elucidated. In this study, we examined the expression of ASPP1 and ASPP2 in ESCC 
to evaluate their prognostic values.
Methods: The protein expression of ASPP1, ASPP2, and P53 in 175 specimens of ESCC was detected using immuno‑
histochemical staining; their expression in cancerous and noncancerous tissues was scored according to the stain‑
ing intensity and the percentage of stained cells. The associations of ASPP1, ASPP2, and P53 with clinicopathologic 
parameters, overall survival (OS), and disease‑free survival (DFS) were analyzed.
Results: The protein expression levels of ASPP2 and P53 were significantly higher in cancerous tissues than in 
paired noncancerous tissues (P < 0.001), whereas the expression levels of ASPP1 in the two groups were similar. In 
ESCCs, ASPP1 expression was significantly associated with histological differentiation (P = 0.002) and invasive depth 
(P = 0.014); ASPP2 expression was associated with age (P = 0.029) and histological differentiation (P < 0.001); and P53 
expression was associated with age (P = 0.021) and tumor size (P = 0.040). No correlations were found between ASPP1, 
ASPP2, and P53 expression. Survival analysis revealed that high ASPP2 expression was significantly associated with 
increased 5‑year OS (P = 0.001) and DFS rates (P = 0.010) and that high P53 expression was significantly associated 
with a reduced 5‑year DFS rate of ESCC patients (P = 0.015). Multivariate Cox analysis indicated that ASPP2 was an inde‑
pendent predictor of OS [hazard ratio (HR): 0.541, 95% confidence interval (CI) 0.363–0.804] and DFS (HR: 0.599, 95% CI 
0.404–0.888) of ESCC patients and that P53 was an independent predictor of DFS (HR: 2.161, 95% CI 1.100–4.245).
Conclusions: ASPP1 might be involved in the progression of ESCC, and ASPP2 was a potential prognostic biomarker 
of ESCC and should be evaluated in future studies.
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a recent study showed that ASPP2 also induced apopto-
sis through a P53-independent mechanism [18]. Addi-
tionally, ASPP2 plays an important role in regulating the 
nuclear factor kappa B subunit 1 (NFκB1) inflammatory 
pathway [19] and in modulating autophagy [18, 20] and 
cell polarity [21, 22].
Although ASPP1 and ASPP2 have been reported to 
play crucial roles in the development of several malignan-
cies, their involvement in ESCC development remains 
undetermined. In this study, we detected the expression 
of ASPP1, ASPP2, and P53 in ESCCs using immunohisto-
chemistry to investigate their prognostic values and rela-
tionships with clinical characteristics of ESCC patients.
Methods
Patient selection
ESCC patients who underwent curative esophagectomy 
between November 2004 and December 2006 at Sun 
Yat-sen University Cancer Center (SYSUCC, Guang-
zhou, China) were selected for this study. All proce-
dures involving human participants were in accordance 
with the standards of the Ethics Committee of SYS-
UCC. Informed consent was obtained from all patients 
included in the study. The following criteria were used 
for patient selection: (1) no radiotherapy, chemotherapy, 
or other cancer treatment before surgery; (2) ESCC diag-
nosed with pathologic examination; (3) R0 resection con-
firmed with postoperative pathologic examination; and 
(4) no distant metastasis diagnosed with imaging before 
surgery, including supraclavicular and abdominal para-
aortic lymph node metastasis. Patients were ineligible 
if they had cervical ESCC, stage T4b ESCC at the time 
of diagnosis, other concomitant malignancies, or severe 
organ disorders. Cancers were pathologically restaged 
according to the 7th edition of the Union for Interna-
tional Cancer Control (UICC) tumor-node-metastasis 
(TNM) staging system.
Follow‑up
All patients were followed up from operation time to 
December 31, 2016 by telephone and return visits, with an 
interval of 3 months, and death was considered an event. 
Post-operative metastasis and recurrence were diagnosed 
on the basis of clinical examination, imaging assessment 
(e.g., barium meal, computed tomography, positron emis-
sion tomography-computed tomography, and endoscopic 
examination), and operative and pathologic examina-
tion. OS was calculated from the time of treatment to the 
date of death or the last follow-up. Disease-free survival 
Background
Esophageal carcinoma is the eighth most prevalent can-
cer and the seventh leading cause of cancer-related death 
worldwide [1] and is the fourth leading cause of cancer-
related death in China [2]. The most common histologi-
cal type of esophageal carcinoma in China is esophageal 
squamous cell carcinoma (ESCC) [1]. The 5-year overall 
survival (OS) rate of ESCC patients after esophagectomy 
has significantly increased over the past several decades 
but remains approximately 20% [3–5]. The late appear-
ance of symptoms, rapid progression, local recurrence, 
and metastasis are the main reasons for the low survival 
rate [6–9]. However, the molecular mechanism of ESCC 
genesis and progression is not well understood, and bio-
markers for predicting clinical outcome of ESCC patients 
are unavailable. Therefore, there is an urgent need to 
identify sensitive and specific biomarkers for ESCC.
The well-known tumor suppressor protein P53 has 
been reported to be involved in the development of 
many types of cancer, including esophageal carcinoma 
[10]. Over 10  years ago, two proteins both containing a 
large number of ankyrin (Ank) repeat sequences, an Src-
homology 3 (SH3) domain, and a proline-rich domain 
were identified as activators for P53 apoptotic function 
and were thus named apoptosis-stimulating P53-binding 
protein 1 (ASPP1) and 2 (ASPP2) [11, 12]. ASPP1 and 
ASPP2 have been reported to play important roles in the 
developement, progression, metastasis, and prognosis of 
cancer. Samuels-Lev et  al. [11] and Slee et  al. [12] have 
demonstrated a specific effect of ASPP1 and ASPP2 in 
breast cancer on the apoptotic and transactivation func-
tions of P53 for the expression of proapoptotic targets, 
such as Bax, P53 up-regulated modulator of apoptosis 
(PUMA), and P53-induced gene 3 (PIG3), through com-
bination with P53 via the Ank sequence and SH3 domain. 
However, ASPP1 and ASPP2 failed to affect the cell cycle 
arrest function of P53 under the same conditions. ASPP1 
and ASPP2 could mediate the cell fate transition between 
life and death. Sgroi et  al. [13] found that invasive and 
metastatic breast cancer tissue exhibited reduced ASPP2 
expression compared with normal breast tissue, suggest-
ing a possible role of ASPP2 in breast cancer progression 
and metastasis. Mak et al. [14] reported the down-regula-
tion of ASPP2 in choriocarcinoma, which contributed to 
the increased migratory potential of the tumor cells. High 
ASPP2 expression has been reported to predict good 
prognosis in some tumors, including breast cancer [15], 
non-small cell lung cancer [16], diffuse large B cell lym-
phoma, and follicular center lymphoma [17]. Moreover, 
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(DFS) was defined as the duration between operation and 
relapse, metastasis, or cancer-related diseases. Clinico-
pathologic data were obtained from pathologic reports, 
medical records, laboratory examination, and imaging, 
primarily including information of age, gender, histologi-
cal differentiation, tumor location, pTNM stage, T status 
(invasive depth), N status (lymph node metastasis), tumor 
size, smoking habit, alcohol consumption, postoperative 
radiotherapy and chemotherapy.
Immunohistochemistry
The appropriate paraffin-embedded specimen blocks of 
each case of ESCC were obtained from the Department 
of Pathology. If possible, adjacent non-cancerous tis-
sue specimens were processed and compared with the 
cancerous specimens as matched pairs. Tissue sections 
(4 µm thick) were dried at 60°C for 3–4 h, deparaffinized 
with three 10-min washes in xylene, and rehydrated in 
decreasing concentrations of ethanol in distilled water. 
Then, the tissue sections were treated with 3% hydro-
gen peroxide for 10  min to block endogenous peroxi-
dase activity. After washing 10  min in phosphate buffer 
solution (PBS, ZSGB-BIO, Beijing, China) for three 
times, the sections were soaked in boiling sodium citrate 
buffer (ZSGB-BIO) for 20 min in microwave oven. When 
cooled to room temperature, the sections were washed 
5  min in PBS for three times and were incubated over-
night at 4°C with rabbit polyclonal anti-ASPP1 antibody 
(bs-1282R; dilution, 1:100; Bioss, Beijing, China), rab-
bit polyclonal anti-ASPP2 antibody (bs-1283R; dilution, 
1:300; Bioss), or mouse monoclonal antibody against 
wild-type and mutated P53 (ZM-0408; dilution, 1:100; 
ZSGB-BIO) and followed by incubation with reagent A 
[secondary antibody of GTVision™ III Detection System/
Mo&Rb, Gene Tech Biotechnology (Shanghai) Com-
pany Limited, Shanghai, China] for 30 min at 37°C. The 
colorimetric reaction was observed under a microscope 
after incubating with reagent B (GTVision™ III Detection 
System/Mo&Rb). Sections were counterstained with 5% 
hematoxylin for 5  min. Finally, the sections were blued 
in 1% hydrochloric-acid alcohol, dehydrated in increas-
ing concentrations of ethanol, cleared with xylene, and 
mounted in neutral gum under a coverslip. The sections 
treated without primary antibody were used as negative 
control. For positive controls, non-small cell lung cancer 
(for ASPP1 and ASPP2) [16] and ESCC sections (for P53) 
[23] were stained using the same protocol.
Evaluation of immunohistochemical staining
Using a high-power (400×) microscope (Eclipse 80i, 
Nikon, Tokyo, Japan), ASPP1, ASPP2, and P53 expres-
sion was evaluated by two experienced pathologists 
independently, without knowledge of the clinical informa-
tion. For each section, five random non-overlapping fields 
containing at least 200 cells per field were observed and 
scored based on the percentage of positively stained cells 
(0%–100%) and the staining intensity (score 0 for nega-
tive staining, 1 for weak staining, 2 for moderate stain-
ing, and 3 for strong staining). The immunoreactive score 
(IRS) was calculated with the formula, the percentage of 
positive cells × the staining intensity × 100, to produce a 
value between 0 and 300. Patients were divided into low 
and high expression groups according to the median IRSs.
Statistical analysis
All data were analyzed using SPSS16.0 statistical soft-
ware (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 
5 software (GraphPad Software Inc., La Jolla, CA, USA). 
Paired and unpaired Student’s t tests were performed to 
compare ASPP1, ASPP2, and P53 expression between 
ESCCs and noncancerous tissues. The relationships of 
ASPP1, ASPP2, and P53 expression with the clinico-
pathologic parameters were assessed using Chi-square 
and Fisher’s exact tests. Spearman’s rank correlation was 
used to analyze the correlations between ASPP1, ASPP2, 
and P53 expression. Kaplan–Meier survival analysis and 
log-rank tests were used to evaluate the 5-year OS and 
DFS rates of ESCC patients. Cox univariate analysis was 
used to determine the prognostic significance of vari-
ables, and Cox multivariate analysis was applied to iden-
tify independent prognostic factors for ESCC. For all 
results, P < 0.05 was considered statistically significant.
Results
The expression of ASPP1, ASPP2, and P53 in ESCCs 
and noncancerous tissues
We examined the expression of ASPP1, ASPP2, and P53 
in 175 ESCC tissues and 105 paired noncancerous tissues 
using immunohistochemical staining. The cases with 
insufficient tissue for immunohistochemical staining 
were excluded from relevant analysis. Patients’ character-
istics are listed in Table 1. The median IRSs were 100 for 
ASPP1, 110 for ASPP2, and 100 for P53.
Immunohistochemical staining showed that ASPP1 
was expressed in the cytoplasm, ASPP2 was expressed 
primarily in the perinuclear cytoplasm, and P53 was 
expressed in the nucleus (Fig. 1). In the paired analysis, 
the rate of high ASPP1 expression was similar between 
ESCCs and noncancerous tissues [44.6% (45/101) vs. 
45.5% (46/101), P  =  0.897], whereas the rates of high 
ASPP2 and P53 expression were both significantly higher 
in ESCCs than in noncancerous tissues [51.0% (51/100) 
vs. 10.0% (10/100), P  <  0.001; 54.4% (56/103) vs. 2.9% 
(3/103), P  <  0.001] (Fig.  2). The results of the unpaired 
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analysis were consistent with those of the paired analysis 
(Fig. 3).
Relationships between ASPP1, ASPP2, P53 expression 
and clinical characteristics of ESCC patients
To better understand the clinical significance of ASPP1, 
ASPP2, and P53 in ESCC, we examined the relation-
ships between their expression and clinical characteris-
tics of ESCC patients (Table  1). ASPP1 expression was 
associated with histological differentiation (P  =  0.002) 
and invasive depth (P  =  0.014). ASPP2 expression was 
associated with histological differentiation (P  <  0.001) 
and age (P = 0.029). P53 expression was associated with 
tumor size (P = 0.040) and age (P = 0.021). However, no 
correlation was found between the expression of ASPP1 
and P53 (R = 0.033, P = 0.671), between the expression 
of ASPP2 and P53 (R = 0.036, P = 0.647), or between the 
expression of ASPP1 and ASPP2 (R = 0.045, P = 0.895).
Table 1 Associations between  the expression of  apoptosis-stimulating P53-binding protein 1 (ASPP1) and  2 (ASPP2) 
and P53 and clinicopathologic characteristics of the 175 esophageal squamous cell carcinoma (ESCC) patients
a The cases with insufficient tissue for immunohistochemical staining were excluded from relevant analysis
Characteristic ASPP1 expression 
[cases (%)]
P value ASPP2 expression 
[cases (%)]
P value P53 expression [cases 
(%)]
P value
Low High Low High Low High
Totala 79 95 75 98 82 91
Gender 0.569 0.713 0.794
 Male 56 (70.9) 71 (74.7) 54 (72.0) 73 (74.5) 58 (70.7) 66 (72.5)
 Female 23 (29.1) 24 (25.3) 21 (28.0) 25 (25.5) 24 (29.3) 25 (27.5)
Age (years) 0.495 0.029 0.021
 ≤60 57 (72.2) 64 (67.4) 45 (60.0) 74 (75.5) 63 (76.8) 55 (60.4)
 >60 22 (27.8) 31 (32.6) 30 (40.0) 24 (24.5) 19 (23.2) 36 (39.6)
Histological differentiation 0.002 <0.001 0.301
 Well 14 (17.7) 40 (42.1) 15 (20.0) 39 (39.8) 21 (25.6) 32 (35.2)
 Moderate 48 (60.8) 41 (43.2) 38 (50.7) 51 (52.0) 44 (53.7) 46 (50.5)
 Poor 17 (21.5) 14 (14.7) 22 (29.3) 8 (8.2) 17 (20.7) 13 (14.3)
Tumor location 0.459 0.311 0.446
 Upper thoracic esophagus 8 (10.1) 5 (5.2) 7 (9.3) 7 (7.1) 7 (8.5) 7 (7.7)
 Middle thoracic esophagus 55 (69.6) 68 (71.6) 47 (62.7) 72 (73.5) 60 (73.2) 60 (65.9)
 Lower thoracic esophagus 16 (20.3) 22 (23.2) 21 (28.0) 19 (19.4) 15 (18.3) 24 (26.4)
pTNM stage 0.628 0.148 0.400
 I–II 37 (46.8) 48 (50.5) 33 (44.0) 54 (55.1) 44 (53.7) 43 (47.3)
 III 42 (53.2) 47 (49.5) 42 (56.0) 44 (44.9) 38 (46.3) 48 (52.7)
Invasive depth 0.014 0.920 0.145
 T1–2 14 (17.7) 30 (31.6) 18 (24.0) 26 (26.5) 26 (31.7) 18 (19.8)
 T3 62 (78.5) 55 (57.9) 51 (68.0) 65 (66.3) 49 (59.8) 67 (73.6)
 T4 3 (3.8) 10 (10.5) 6 (8.0) 7 (7.2) 7 (8.5) 6 (6.6)
Lymph node metastasis 0.708 0.162 0.156
 Absence 36 (45.6) 46 (48.4) 31 (41.3) 51 (52.0) 44 (53.7) 39 (42.9)
 Presence 43 (54.4) 49 (51.6) 44 (58.7) 47 (48.0) 38 (46.3) 52 (57.1)
Tumor size (cm) 0.423 0.463 0.040
 <5 61 (77.2) 78 (82.1) 57 (76.0) 79 (80.6) 70 (85.4) 66 (72.5)
 ≥5 18 (22.8) 17 (17.9) 18 (24.0) 19 (19.4) 12 (14.6) 25 (27.5)
Smoking 0.924 0.807 0.171
 Yes 46 (58.2) 56 (58.9) 43 (57.3) 58 (59.2) 42 (51.2) 56 (61.5)
 No 33 (41.8) 39 (41.1) 32 (42.7) 40 (40.8) 40 (48.8) 35 (38.5)
Alcohol drinking 0.537 0.478 0.568
 Yes 25 (31.6) 26 (27.4) 20 (26.7) 31 (31.6) 22 (26.8) 28 (30.8)
 No 54 (68.4) 69 (72.6) 55 (73.3) 67 (68.4) 60 (73.2) 63 (69.2)
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Relationships between ASPP1, ASPP2, P53 expression 
and survival of ESCC patients
To further evaluate the prognostic value of ASPP1, 
ASPP2, and P53 in ESCC, we performed Kaplan–Meier 
survival analysis and log-rank tests. ASPP1 expres-
sion was not associated with survival rate, whereas high 
ASPP2 expression was significantly associated with 
increased 5-year OS rate (51.0% vs. 31.7%, P = 0.001) and 
5-year DFS rate as compared with low ASPP2 expression 
(46.5% vs. 32.0%, P = 0.010), and low P53 expression was 
associated with increased 5-year DFS rate as compared 
with high P53 expression (78.6% vs. 61.4%, P  =  0.015) 
(Fig. 4).
Univariate Cox analysis also indicated that low ASPP2 
expression was a significant predictor of short OS [haz-
ard ratio (HR): 0.527, 95% confidence interval (CI) 
Fig. 1 Immunohistochemical staining of apoptosis‑stimulating P53‑binding protein 1 (ASPP1) and 2 (ASPP2) and P53 in esophageal squamous cell 
carcinoma (ESCC) and noncancerous tissues. ASPP1 is primarily expressed in the cytoplasm and is strongly positive in noncancerous tissues and 
ESCCs. ASPP2 is primarily expressed in the perinuclear region and is moderately positive in noncancerous tissues while strongly positive in ESCC. 
P53 is primarily expressed in the nucleus in most ESCCs, but is seldom detected in noncancerous tissues
Fig. 2 Expression of ASPP1, ASPP2, and P53 in paired ESCC and noncancerous tissues. IRS: immunoreactive score. The cases with insufficient tis‑
sue for immunohistochemical staining were excluded from relevant analysis. ASPP1 expression is not significantly different between the paired 
ESCC and noncancerous tissues (P = 0.897). Both ASPP2 and P53 expression are significantly higher in ESCCs than in noncancerous tissues (both 
P < 0.001)
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0.355–0.782, P  =  0.001] and DFS (HR: 0.606, 95% CI 
0.412–0.891, P = 0.011) and that high P53 expression was 
a predictor of short DFS (HR: 2.198, 95% CI 1.144–4.224, 
P  =  0.018); ASPP1 expression had no significant asso-
ciation with survival (Table 2). Multivariate Cox analysis 
indicated that low ASPP2 expression was an independent 
predictor of short OS (HR: 0.541, 95% CI 0.363–0.804, 
P  =  0.002) and DFS (HR: 0.599, 95% CI 0.404–0.888, 
P = 0.011) and that low P53 expression was an independ-
ent predictor of long DFS (HR: 2.161, 95% CI 1.100–
4.245, P = 0.025) (Table 3). Other significant predictors 
of OS and DFS included pTNM stage, invasive depth, 
Fig. 3 Average levels of ASPP1, ASPP2, and P53 expression in unpaired ESCC and noncancerous tissues. The cases with insufficient tissue for immu‑
nohistochemical staining were excluded from relevant analysis. Average level of ASPP1 expression is not significantly different between ESCC and 
noncancerous tissues (P = 0.904). Average levels of both ASPP2 and P53 expression are significantly higher in ESCCs than in noncancerous tissues 
(both P < 0.001). The horizontal lines in the boxes represent the average expression levels
Fig. 4 Kaplan–Meier survival curves of ESCC patients with low and high expression of ASPP1, ASPP2, and P53. The overall survival (OS) and disease‑
free survival (DFS) curves of patients with high ASPP1 expression are not significantly different from those of patients with low ASPP1 expression. 
Patients with high ASPP2 expression have higher 5‑year OS and DFS rates than those with low ASPP2 expression. Patients with high P53 expression 
have a lower 5‑year DFS rate than those with low P53 expression, whereas the 5‑year OS rates were similar for both groups
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lymph node metastasis, radiotherapy, and chemother-
apy (Table  2), whereas only invasive depth, lymph node 
metastasis, and radiotherapy were independent predic-
tors (Table 3). 
Because tumor stage was closely associated with the 
prognosis of ESCC patient, we performed subgroup 
analysis according to the stages. For patients with stage 
I–II ESCC, the expression of ASPP1 showed no prognos-
tic value; for patients with stage III ESCC, high ASPP1 
expression was associated with long OS (P  =  0.012) 
and DFS (P =  0.032) (Fig. 5). However, ASPP2 and P53 
expression showed no prognostic values for patients with 
either stage I–II or III ESCC (data not shown).
Discussion
In the present study, we demonstrated that ASPP2 
expression was significantly increased in ESCC and 
was associated with histological differentiation and age. 
ASPP2 was an independent predictor of OS and DFS of 
ESCC patients. Although the expression of ASPP1 was 
not associated with overall prognosis, it was associated 
with the prognosis of patients with stage III disease.
ASPP2 is commonly considered a tumor suppressor, 
and its expression is often reduced in malignant tumors 
[14, 24, 25]. However, inconsistent with previous reports, 
our results indicated that ASPP2 expression was signifi-
cantly increased in ESCCs as compared with noncancer-
ous tissues, suggesting that ASPP2 might be involved in 
ESCC tumorigenesis. Interestingly, the expression of the 
well-known tumor suppressor p53 was also reported to 
be increased in several types of cancer, including ESCC, 
and its high expression was related with a mutation [26, 
27]. It is well known that protein phosphorylation and 
dephosphorylation serve as “signal switch” and are the 
most important mechanisms of signaling pathway regula-
tion. Wild-type (unphosphorylated) P53 is usually unde-
tectable using immunohistochemistry, whereas mutant 
(phosphorylated) P53 with dominant-negative activities 
Table 2 Univariate Cox regression analysis of predictors for OS and DFS of ESCC patients
OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval
Variable OS DFS
HR 95% CI P value HR 95% CI P value
Gender (male vs. female) 1.367 0.893–2.093 0.150 1.343 0.881–2.046 0.170
Age (≤60 vs. >60 years) 1.168 0.769–1.774 0.466 1.040 0.688–1.572 0.852
Histological differentiation (well vs. moderate vs. poor) 1.192 0.895–1.587 0.230 1.123 0.848–1.487 0.419
Tumor location (upper vs. middle vs. lower thoracic esophagus) 0.935 0.642–1.363 0.728 0.980 0.676–1.420 0.915
pTNM stage (III vs. I–II) 2.401 1.594–3.616 <0.001 2.405 1.611–3.591 <0.001
Invasive depth (T4 vs. T3 vs. T1–2) 1.672 1.145–2.442 0.008 1.663 1.143–2.418 0.008
N status (N1‑3 vs. N0) 2.443 1.609–3.708 <0.001 2.383 1.586–3.581 <0.001
Tumor size (<5 vs. ≥5 cm) 1.061 0.655–1.718 0.810 1.083 0.676–1.735 0.740
ASPP1 expression (low vs. high) 0.942 0.641–1.383 0.761 0.942 0.641–1.383 0.761
ASPP2 expression (high vs. low) 0.527 0.355–0.782 0.001 0.606 0.412–0.891 0.011
P53 expression (high vs. low) 1.072 0.721–1.596 0.731 2.198 1.144–4.224 0.018
Smoking (yes vs. no) 1.023 0.686–1.527 0.910 1.020 0.689–1.509 0.921
Alcohol drinking (yes vs. no) 0.869 0.568–1.329 0.517 0.786 0.521–1.185 0.251
Radiotherapy (yes vs. no) 0.742 0.421–1.307 0.301 0.567 0.333–0.967 0.037
Chemotherapy (yes vs. no) 0.681 0.432–1.072 0.097 0.580 0.374–0.900 0.015
Table 3 Multivariate Cox regression analysis of predictors for OS and DFS of ESCC patients
– The variables with a P value > 0.05 were not included in the multivariate analysis. Abbreviations as in Table 2
Variable OS DFS
HR 95% CI P value HR 95% CI P value
Invasive depth (T4 vs. T3 vs. T1–2) 1.646 1.083–2.501 0.020 1.532 1.028–2.283 0.036
N status (N1–3 vs. N0) 2.248 1.474–3.426 <0.001 2.139 1.405–3.256 <0.001
ASPP2 expression (high vs. low) 0.541 0.363–0.804 0.002 0.599 0.404–0.888 0.011
P53 expression (high vs. low) – – – 2.161 1.100–4.245 0.025
Radiotherapy (yes vs. no) – – – 0.575 0.374–0.990 0.046
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and oncogenic properties can be detected because its 
half-life is much longer [28–32]. High expression of 
mutant (phosphorylated) P53 has been observed in many 
malignancies [11, 29, 33–35]. Protein expression is highly 
cell environment-specific and is regulated both geneti-
cally and epigenetically. Similar to P53, ASPP2 is also 
a tumor suppressor that is up-regulated in ESCC. We 
hypothesized that high ASPP2 expression in ESCC may 
be due to epigenetic alterations, such as phosphorylation 
and methylation.
Moreover, some proteins, such as nuclear factor eryth-
roid-2 related factor 2 (NRF2), play important roles in 
protecting normal cells from tumorigenesis or disease 
development, but can be hijacked by cancer cells upon 
neoplasm initiation [36, 37]. It has been reported that 
NFR2 functions as a suppressor in carcinomas through 
autophagy-related [38] and inflammation-related can-
cer signaling pathways [39, 40]. Mounting evidence has 
suggested that ASPP2 also plays an antitumor role in 
malignancies through autophagy- [18] and inflamma-
tory-related pathways independent of P53 [19]. Thus, 
we suggest that ASPP2 may function through similar 
pathways to NRF2. However, the underlying mechanism 
requires further investigation.
Furthermore, our results showed that high ASPP2 
expression was associated with high degree of differ-
entiation of ESCC, suggesting that ASPP2 may repress 
the progression  of ESCC. We also found that high P53 
expression was associated with large tumor size, indicat-
ing that mutant P53 expression may be involved in tumor 
progression, which is consistent with a recent study 
[23]. Although we did not detect a difference in ASPP1 
expression between ESCCs and noncancerous tissues, 
high ASPP1 expression was associated with high degree 
of histological differentiation and shallow invasion of 
ESCCs, suggesting that high ASPP1 expression may 
inhibit tumor progression.
According to our results, low ASPP2 expression inde-
pendently predicted poor prognosis of ESCC patients, 
which is consistent with previous reports of other can-
cers [15–17]. More aggressive therapy modality (e.g., 
including chemotherapy and radiotherapy) and close 
follow-up may be necessary for patients with low ASPP2 
expression. Our study confirmed that high P53 expres-
sion was an independent predictor of short DFS, which 
was consistent with the results reported in literature [23, 
41, 42]. Similar to ASPP2, patients with high P53 expres-
sion need more aggressive therapy modality and close 
follow-up to reduce the chance of relapse or metastasis. 
Although high ASPP1 expression was not associated with 
the prognosis of the whole cohort, it was associated with 
prolonged OS and DFS of patients with stage III disease. 
We hypothesize that ASPP1 mainly suppress tumor pre-
gression in patients with advanced ESCC.
As their names “apoptosis-stimulating protein of P53 1 
and 2” suggest, ASPP1 and ASPP2 were initially reported 
to function in a P53-dependent manner. Samuels-Lev 
et al. [11] found ASPP2 down-regulation in tumors with 
wild-type P53 but not in those with mutant P53. Iwabu-
chi et al. [43] suggested that ASPP1 and ASPP2 exerted 
their function of inhibiting tumorigenesis only in the 
presence of wild-type P53. However, later studies showed 
that ASPP2 played tumor-suppressing roles independent 
of P53, such as enhancing colorectal cancer cell apop-
tosis through autophagy inhibition [18], inhibiting cell 
migration through Src inactivation [14], and stimulating 
Ras-induced senescence through direct interactions with 
Ras-GTP [44]. Additionally, we did not find any correla-
tion among ASPP1, ASPP2, and P53, indicating that they 
may all function independently. However, in this study, 
we only detected ASPP1 and ASPP2 expression using 
immunohistochemistry and the results need further 
experiments to verify and explore.
Conclusions
ASPP1 may mainly function in advanced ESCCs rather than 
the gamut or early-stage ESCCs. ASPP2 may be an inde-
pendent prognostic biomarker in ESCC, and patients with 
low ASPP2 expression may need more aggressive therapy 
modality and close follow-up. In the future, we will conduct 
in vivo and in vitro experiments to verify the immunohisto-
chemistry results and further explore the biological mecha-
nism of ASPP1’s and ASPP2’s functions in ESCC.
Fig. 5 Kaplan–Meier survival curves of ESCC patients at different 
stages with low and high expression of ASPP1. For patients with 
stage I–II ESCC, the OS and DFS curves of patients with high ASPP1 
expression are not significantly different from those of patients with 
low ASPP1 expression. High ASPP1 expression was associated with 
long OS and DFS in patients with stage III ESCC
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